Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials

While Eli Lilly dominates the GLP-1 weight-loss drug market and Novo Nordisk struggles to regain ground, Pfizer is positioning itself as a surprise contender. After dropping its original GLP-1 candidate, Pfizer acquired an alternative drug in development and is now running 10 late-stage trials. The company's key differentiator is a monthly injection option, which could offer greater convenience than competitors' weekly or daily dosing. With a high dividend yield of 5.5% and an inflection point potentially closer than Wall Street believes, Pfizer may represent an overlooked opportunity for long-term dividend investors.